Tommy B Andersson

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis
    L Afzelius
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D, , Sweden
    Mol Pharmacol 59:909-19. 2001
  2. doi request reprint Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran
    Kerstin Kenne
    Safety Assessment, AstraZeneca R and D Sodertalje, S 151 85 Södertälje, Sweden
    Toxicol In Vitro 22:730-46. 2008
  3. doi request reprint The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human
    Tommy B Andersson
    DMPK Innovative Medicines, AstraZeneca R and D, Mölndal S 431 83 Mölndal, Sweden
    Expert Opin Drug Metab Toxicol 8:909-20. 2012
  4. ncbi request reprint An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates
    Tommy B Andersson
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D, S 431 83 Molndal, Sweden
    Drug Metab Dispos 32:715-21. 2004
  5. ncbi request reprint An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
    T B Andersson
    Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca Research and Development, Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 29:712-20. 2001
  6. ncbi request reprint Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4
    Xue Qing Li
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, Sweden
    J Pharmacol Exp Ther 315:777-87. 2005
  7. doi request reprint Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system
    Maria Ulvestad
    DMPK Innovative Medicines, AstraZeneca R and D Molndal, Molndal, Sweden
    J Pharmacol Exp Ther 343:145-56. 2012
  8. ncbi request reprint HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans
    Kajsa P Kanebratt
    Development DMPK and Bioanalysis, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 36:137-45. 2008
  9. ncbi request reprint The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds
    Tommy B Andersson
    Clinical Pharmacology and DMPK, AstraZeneca R and D, Molndal, Sweden
    Methods Mol Biol 640:375-87. 2010
  10. ncbi request reprint Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques
    Lovisa Afzelius
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Drug Metab Dispos 32:1218-29. 2004

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis
    L Afzelius
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D, , Sweden
    Mol Pharmacol 59:909-19. 2001
    ..5 log units of the experimental K(i) values. The amino acids in the active site showed complementary features to the grid interaction energies in the 3D-QSAR model and were also in agreement with mutagenesis studies...
  2. doi request reprint Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran
    Kerstin Kenne
    Safety Assessment, AstraZeneca R and D Sodertalje, S 151 85 Södertälje, Sweden
    Toxicol In Vitro 22:730-46. 2008
    ....
  3. doi request reprint The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human
    Tommy B Andersson
    DMPK Innovative Medicines, AstraZeneca R and D, Mölndal S 431 83 Mölndal, Sweden
    Expert Opin Drug Metab Toxicol 8:909-20. 2012
    ..The long-term stability of key cell functions, for example, the drug-metabolizing cytochrome P450 (CYP) enzyme activities, in culture is especially useful in drug metabolism, disposition and toxicity studies...
  4. ncbi request reprint An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates
    Tommy B Andersson
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D, S 431 83 Molndal, Sweden
    Drug Metab Dispos 32:715-21. 2004
    ..This study points to the uncertainty in calculating in vivo kinetics from in vitro enzyme kinetic data. The in vitro metabolic screening can thus be questioned as a compound selection tool without a proven in vitro-in vivo correlation...
  5. ncbi request reprint An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
    T B Andersson
    Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca Research and Development, Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 29:712-20. 2001
    ....
  6. ncbi request reprint Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4
    Xue Qing Li
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, Sweden
    J Pharmacol Exp Ther 315:777-87. 2005
    ..On the other hand, the use of the S-enantiomer results in less complex enzyme kinetics than those of the racemate; thus, the outcome of its clinical use is more predictable...
  7. doi request reprint Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system
    Maria Ulvestad
    DMPK Innovative Medicines, AstraZeneca R and D Molndal, Molndal, Sweden
    J Pharmacol Exp Ther 343:145-56. 2012
    ..In conclusion, freshly isolated human hepatocytes cultured in a 3D bioreactor system preserve both OATP1B1 and CYP3A4 activities, allowing long-term in vitro studies on drug disposition and toxicity...
  8. ncbi request reprint HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans
    Kajsa P Kanebratt
    Development DMPK and Bioanalysis, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 36:137-45. 2008
    ..The present study shows that HepaRG cells are a valuable model to be used for prediction of induction of drug-metabolizing P450 enzymes in vivo in humans...
  9. ncbi request reprint The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds
    Tommy B Andersson
    Clinical Pharmacology and DMPK, AstraZeneca R and D, Molndal, Sweden
    Methods Mol Biol 640:375-87. 2010
    ..HepaRG cells could therefore be an alternative to human hepatocytes in investigating drug metabolism and induction of drug-metabolising enzymes...
  10. ncbi request reprint Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques
    Lovisa Afzelius
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Drug Metab Dispos 32:1218-29. 2004
    ..This is a dynamic process since the crystal structures are improving with time and, therefore, the answers to the models are also changing accordingly...
  11. doi request reprint Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition
    Patrik Lundquist
    CNS and Pain Innovative Medicines DMPK, AstraZeneca R and D, Sodertalje, P L, G E, C S, J L, J J, J H, L A Cardiovascular and Gastrointestinal Innovative Medicines DMPK, AstraZeneca R and D, Molndal, P L, T B A Department of Pharmacy, Uppsala University, Uppsala, P L and Section of Pharmacogenetics, Departments of Physiology and Pharmacology, Karolinska Institutet, Stockholm, T B A, Sweden
    Drug Metab Dispos 42:448-58. 2014
    ....
  12. doi request reprint Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells
    Malin Darnell
    Clinical Pharmacology and DMPK, AstraZeneca R and D, Molndal, Sweden
    Drug Metab Dispos 38:491-7. 2010
    ..The results also suggest that inhibition of hepatic P-gp is involved in the erythromycin-ximelagatran interaction seen in clinical studies...
  13. ncbi request reprint Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions
    Eva Bredberg
    Experimental Medicine, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 42:765-77. 2003
    ..In vitro studies have shown no evidence for involvement of cytochrome P450 (CYP) enzymes in either the bioactivation or the elimination of melagatran...
  14. doi request reprint In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system
    Malin Darnell
    DMPK Innovative Medicines, AstraZeneca R and D Molndal, Molndal, Sweden
    J Pharmacol Exp Ther 343:134-44. 2012
    ..Thus, the incubation time can be increased from a few hours in suspension to several days in 3D cultures, which opens up for detection of metabolites from slowly metabolized drugs...
  15. ncbi request reprint Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole
    A Abelö
    AstraZeneca R and D, Molndal, Sweden
    Drug Metab Dispos 28:58-64. 2000
    ..CYP3A4 and CYP2C9 seem to contribute as low-affinity enzymes in both reactions. The sulfone metabolite was formed mainly from CYP3A4. Stereoselectivity in CYP3A4-, CYP2C19-, and CYP2C9-mediated metabolic pathways was demonstrated...
  16. doi request reprint The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions
    Patrik Lundquist
    CNS and Pain Innovative Medicines DMPK, AstraZeneca R and D, Sodertalje, P L, J L, A K S S, E F, J J, J B, J H, L A Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R and D, Molndal, P L, T B A Department of Pharmacy, Uppsala University, Uppsala, P L and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, T B A, Sweden
    Drug Metab Dispos 42:469-80. 2014
    ....
  17. ncbi request reprint Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors
    Lovisa Afzelius
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D, S 431 83 Molndal, Sweden
    J Med Chem 47:907-14. 2004
    ..This approach offers the possibility to derive predicitve 3D-QSAR models without the need for an alignment rule for chemically diverse ligands and in the absence of target protein crystal structure information...
  18. doi request reprint Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model
    Patrik Lundquist
    CNS and Pain Innovative Medicines DMPK, AstraZeneca R and D, Södertälje P L, J L, U F, I S, J J, S B, J H, L A Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R and D, Mölndal P L, T B A Department of Pharmacy, Uppsala University, Uppsala P L and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm T B A, Sweden
    Drug Metab Dispos 42:459-68. 2014
    ....
  19. ncbi request reprint Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates
    Collen M Masimirembwa
    AstraZeneca R and D Mäolndal, S 431 83 Molndal, Sweden
    Methods Enzymol 357:133-44. 2002
  20. ncbi request reprint Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
    Xue Qing Li
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 32:821-7. 2004
    ..The inhibitory potency of rabeprazole was relatively lower than the other PPIs, but its thioether analog showed potent inhibition on the P450 enzymes investigated, which may be clinically significant...
  21. ncbi request reprint Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate
    Xue Qing Li
    Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca Research and Development, Molndal, Sweden
    J Pharmacol Exp Ther 300:399-407. 2002
    ..These data show that CYP2C8 is the main hepatic isoform responsible for the metabolism of AQ. The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity...
  22. ncbi request reprint Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies
    Kajsa P Kanebratt
    Development DMPK and Bioanalysis, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 36:1444-52. 2008
    ....
  23. doi request reprint In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 39:703-10. 2011
    ..Although ticagrelor exhibited a tendency for CYP2B6 and CYP2C9 induction, its potential to cause drug interactions via the induction of these enzymes is low when its exposure at a therapeutic dose is considered...
  24. ncbi request reprint Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions
    Diansong Zhou
    Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Wilmington, DE 19810, USA
    Drug Metab Dispos 34:976-83. 2006
    ..The MetaSite methodology is automated, rapid, and has relatively accurate predictions compared with the docking methodology used in this study...
  25. ncbi request reprint Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors
    Lovisa Afzelius
    Department of Organic Pharmaceutical Chemistry, Biomedical Center, Uppsala University, Uppsala, Sweden
    J Comput Aided Mol Des 16:443-58. 2002
    ..5 log units. The discriminant model will be useful in screening for CYP2C9 inhibitors from large compound collections. The 3D-QSAR model will be used during lead optimization to avoid chemistry that result in inhibition of CYP2C9...
  26. ncbi request reprint Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
    A Abelö
    AstraZeneca R and D Molndal, Molndal, Sweden
    Drug Metab Dispos 28:966-72. 2000
    ..CYP2C19 favors 5-hydroxylation of the pyridine group of R-omeprazole, whereas the same enzyme mainly 5-O-demethylates S-omeprazole in the benzimidazole group. Sulfoxidation mediated by CYP3A4 highly favors the S-form...
  27. ncbi request reprint In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery
    C M Masimirembwa
    Department of DMPK and Bioanalytical Chemistry, AstraZeneca, R and D Mölndal, S431 83 Mölndal, Sweden
    Comb Chem High Throughput Screen 4:245-63. 2001
    ..We will review the utility and limitations of these HTS approaches and highlight on-going developments and emerging technologies to answer metabolism questions at the different stages of the drug discovery process...
  28. ncbi request reprint Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA
    M Ridderström
    Department of DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, Molndal, Sweden
    J Med Chem 44:4072-81. 2001
    ..An inverse pharmacophore model for CYP2C9 was constructed from the selective regions, and the model agreed with the docking of diclofenac where the properties of the ligand overlapped with the pharmacophoric points in the model...
  29. ncbi request reprint Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans
    Kajsa P Persson
    DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, 431 83, Molndal, Sweden
    Pharm Res 23:56-69. 2006
    ..The aim of the study was to investigate the feasibility of predicting human in vivo cytochrome P450 (CYP) induction properties of drugs using in vitro methods...
  30. doi request reprint Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor
    Malin Darnell
    DMPK Centre of Excellence, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Drug Metab Dispos 39:1131-8. 2011
    ....
  31. doi request reprint High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells
    Johan E Karlsson
    Clinical Pharmacology and DMPK, AstraZeneca R and D Molndal, Sweden
    Drug Metab Dispos 38:705-14. 2010
    ..The vesicles are thus well suited to screen for possible substrates and inhibitors in high throughput systems or are used for detailed mechanistic investigations of transporter kinetics of specific substances...
  32. ncbi request reprint Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges
    Collen M Masimirembwa
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Pharmacokinet 42:515-28. 2003
    ....
  33. ncbi request reprint Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research
    C M Masimirembwa
    Department of Pharmacokinetics and Drug Metabolism, AstraZeneca Mölndal, Molndal, Sweden
    Drug Metab Dispos 27:1117-22. 1999
    ..5 microM) and CYP2D6 (IC(50) = 3.5 microM) activities. We have therefore successfully set-up and validated an "in-house" heterologous system for the production of human recombinant CYPs for use in metabolism research...
  34. doi request reprint Cytochrome p450 inhibitory properties of common efflux transporter inhibitors
    Gunilla Englund
    CNS and Pain Innovative Medicines DMPK, AstraZeneca R and D, Södertälje G E, P L, C S, J J, J H, L A Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R and D, Mölndal P L, T B A, D P Department of Pharmacy, Uppsala University, Uppsala P L and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm T B A, Sweden
    Drug Metab Dispos 42:441-7. 2014
    ..Elacridar, described as a potent and selective P-gp inhibitor, displayed modest P450 inhibition in this study and is thus a useful model inhibitor to define the role of P-gp in drug disposition without interference with other processes. ..
  35. ncbi request reprint Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes
    Anna Karin M Sjogren
    Cardiovascular and Metabolic Diseases Innovative Medicines, DMPK, AstraZeneca R and D, 431 83, Molndal, Sweden
    Arch Toxicol 88:1427-37. 2014
    ....
  36. doi request reprint OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture
    Maria Ulvestad
    DMPK Innovative Medicines, AstraZeneca R and D Molndal, Pepparedsleden 1, SE 431 83 Molndal, Sweden
    Biochem Pharmacol 82:1219-26. 2011
    ..In conclusion, plated primary human hepatocytes are useful as an in vitro model for OATP1B1/1B3-mediated uptake studies, but the culture time may substantially change the uptake kinetics...
  37. doi request reprint Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function
    Tasso Miliotis
    AstraZeneca R and D, Innovative Medicines, Molndal, Sweden
    Drug Metab Dispos 39:2440-9. 2011
    ....
  38. ncbi request reprint Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data
    Xue Qing Li
    Department of Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
    Eur J Clin Pharmacol 59:429-42. 2003
    ..This study was performed to further identify the cytochrome P(450) (CYP) enzymes that metabolise major APDs and evaluate the possibility of predicting in vivo drug clearances from in vitro data...
  39. doi request reprint PhRMA white paper on ADME pharmacogenomics
    J Andrew Williams
    Pfizer Global Research and Development, 10646 Science Center Drive CB10, San Diego, CA 92121, USA
    J Clin Pharmacol 48:849-89. 2008
    ..In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry...
  40. ncbi request reprint Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures
    Edward K Ainscow
    Advanced Science and Technology Laboratory, AstraZeneca R and D Charnwood, Loughborough, UK
    Expert Opin Drug Saf 7:351-65. 2008
    ..Despite intensive pre clinical investigations the cellular mechanisms behind the observed hepatic effects remain unknown...
  41. ncbi request reprint Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model
    Ylva Edling
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Nanna Svartz vag 2, Stockholm, Sweden
    Toxicol In Vitro 22:1588-94. 2008
    ..It is concluded that human monocytes might constitute a valuable additional in vitro model for monitoring the basis for cytotoxic action of drugs...
  42. ncbi request reprint Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime
    Susanne Andersson
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Drug Metab Dispos 33:570-8. 2005
    ....
  43. ncbi request reprint Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
    Anna Westlind-Johnsson
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Box 210, SE 171 77 Stockholm, Sweden
    Drug Metab Dispos 31:755-61. 2003
    ....
  44. ncbi request reprint Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells
    Tashinga E Bapiro
    Department of Biochemistry, University of Zimbabwe, Harare, Zimbabwe
    Eur J Clin Pharmacol 58:537-42. 2002
    ..To investigate the inductive effects of twenty-four antiparasitic drugs on cytochrome P450 (CYP) 1A1 and 1A2 enzyme activities...
  45. ncbi request reprint Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells
    Monica Ek
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Pharmacol 74:496-503. 2007
    ....